Cytomedix Completes Patient Enrollment for Diabetic Foot Ulcer Trial

Cytomedix has completed the planned enrollment of 72 patients in the company's ongoing clinical trial to test the safety and effectiveness of its AutoloGel System for the treatment of diabetic foot ulcers.

The clinical trial is an FDA-approved, prospective, randomized, blinded and controlled study of AutoloGel. It involves more than a dozen premier sites throughout the U.S.

The patients undergo up to 12 weeks of treatment, and healed patients are followed for another 12 weeks. Total healing of the wounds is one of the key clinical end points being examined in the clinical trial.